Literature DB >> 745584

Steroid receptors study in breast carcinoma.

Y T Lee, F S Markland.   

Abstract

Estrogen receptors (ER) were measured on specimens taken from 27 patients with benign breast conditions and 109 patients with breast cancer. Using sucrose gradient assay, 15% (4/27) of benign lesions and 56% (61/109) of malignant tumors were estrogen receptor-positive (ER-positive means 8S or 8S+4S levels more than 7 fmoles/mg cytosol protein). Progesterone receptors (PR) were tested on specimens from 28 patients and 39% (10/26) of the cancers were PR-positive. ER protein activity was not correlated with stage, histology, size of primary lesions, or extent of axillary or distant metastasis. Tumors with low ER levels are more likely to recur, and recurrent tumors after longer disease-free intervals are more likely to be ER-positive. Detailed analysis showed that ER levels did correlate with age and serum albumin levels. Concentrations of serum alpha1-globulin were decreased, while IgG and IgM were significantly increased among patients with positive ERs. Eighteen evaluable patients with advanced breast cancer had endocrine therapy, 13 had objective response. Twelve of these 13 had 8S receptor above 10 fmoles/mg, or 4S above 15 moles/mg, or 8S+4S above 25 fmoles/mg. The one exceptional patient had tumor with high PR but without detectable ER.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 745584     DOI: 10.1002/mpo.2950050122

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  4 in total

Review 1.  Patterns of metastasis and natural courses of breast carcinoma.

Authors:  Y T Lee
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

2.  Variability of steroid receptors in multiple biopsies of breast cancer: effect of systemic therapy.

Authors:  Y T Lee
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

3.  Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis.

Authors:  Shu-Rong Zheng; Gui-Long Guo; Wei Zhang; Guan-Li Huang; Xiao-Qu Hu; Jin Zhu; Qi-Di Huang; Jie You; Xiao-Hua Zhang
Journal:  Oncol Rep       Date:  2012-01-12       Impact factor: 3.906

Review 4.  Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Authors:  C K Osborne; A Wakeling; R I Nicholson
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.